



2025 US DOHaD Abstract Submission Process

There will be two types of presentations at the conference: oral and poster, and the top three presenters for each presentation format will be recognized and awarded. At submission, authors can choose a theme that best aligns with their abstract from the following:

Theme 1: Preconception Health

Theme 2: Maternal and Placental Health

Theme 3: Child Health Outcomes

Theme 4: Adult Health Outcomes and Interventions

Presenters can indicate if they are willing to give an oral presentation, but it does not guarantee selection. Leadership and organizing committees will review all abstracts for scientific merit and content. Outstanding abstracts fitting the themes will be selected for oral presentation. All presentations will be in-person, with posters presented during abstract presentation sessions on July 31st and/or August 1st, and specific oral platform presentation times outlined in the final program. Full abstracts will be published in the meeting program.

NOTIFICATION OF ABSTRACT ACCEPTANCE

Authors of abstracts submitted for oral presentation will be notified by e-mail of the US DOHaD Program Committee's decision regarding acceptance of the abstract approximately 3 weeks after the abstract submission deadline. Abstracts submitted for poster presentations will be reviewed on a rolling basis up until the 11:59 PM (EST) June 30, 2025 deadline and will not be eligible for consideration for oral platform presentation format.

Abstract Submission Guidelines

(Based on the [SSR](#) abstract submission process)

1. Membership: Membership in US DOHaD is not a prerequisite for submission of an abstract, however membership is required for award eligibility.

2. Authorship: An individual may be first (presenting) author on no more than two abstracts. An individual may be selected to present only one abstract as an oral talk at the meeting and abstracts not selected for oral presentation will be expected to be presented by the first author as a poster. However, an author's name may appear on multiple abstracts as a co-author. Every author must have a unique e-mail address at which they may be contacted. All authors will be notified of the committee's decision of acceptance/rejection, and mode of presentation (oral/poster). Please remember to contact co-authors prior to submission.

3. Abstract Content: Data and conclusions presented at the meeting must be based on the same research described in the submitted abstract. It is strongly encouraged that the abstract and presentation contain some new and unpublished information. Abstracts must be written in clear, concise, and grammatically correct English. The body of the abstract must contain the following:

1. Statement of specific objectives or hypotheses
2. Brief statement of methods, if pertinent
3. Summary of results (including number of individuals per group or number of replicates per treatment), pertinent data, and statistical analyses
4. Statement of conclusions
5. Financial support may be listed at the end of the abstract but is not required.

4. Abstract Format: The title cannot exceed 150 characters. Type the title in lower case with initial letters capitalized (title case) and use appropriate ending punctuation (e.g., period or question mark). Special characters (e.g., Greek characters) will be retained in the title. Do not use any formatting for genetic or scientific nomenclature such as superscripts, subscripts, bold and italics, they will not be retained. The Abstract—excluding title, authors, and affiliations—may not exceed 500 words. It is recommended that abstracts be created in a word processing program, then cut and pasted into the display box provided on the abstract site. Do not use headers (e.g., objectives, methods) in your abstract. Do not put in any paragraph breaks, do not cite references, and do not include tables or figures. Abstracts may not contain any type of advertising or logo, including trademark and copyright symbols. Use of approved gene and protein nomenclature is strongly encouraged.

5. Certification: The presenting author must certify that the conditions for submission have been satisfied and that all animal and human welfare and ethical considerations have been met. Abstracts that violate these ethics will be rejected. Each co-author must agree in principle with the information and conclusions contained within the abstract.

6. Meeting Attendance: Submission of an abstract constitutes an in-principle agreement that the presenting author will register and attend the meeting to present the abstract if the abstract is accepted for an Oral Presentation or a Poster. The presenting author must register for the Annual Meeting before the registration deadline. If the presenting author has not registered by this deadline and is chosen for

an Oral Talk, the organizing committee will attempt to contact the author. If the presenting author does not respond in a timely manner, another abstract will be chosen for oral presentation.

7. Presentation: The first author must present the abstract. Any exception must be approved by the Program Committee more than one week prior to the start of the meeting. Only an existing co-author of the abstract will be considered an acceptable replacement, and that co-author cannot be presenting another oral presentation at this meeting.

8. Competition: Individuals wishing to be considered for a presentation award must indicate their eligibility at the time the abstract is submitted, be fully qualified to compete for each award indicated, and, as presenting author, have played a major role in the design and execution of the experiments described, analysis of the data, interpretation of the results, and writing of the abstract. The Leadership Council and Organizing Committee will select awardees based on an evaluation of the presented abstracts. Learn more about presentation awards and eligibility on our [Awards page](#).

9. Withdrawal: If an abstract must be withdrawn, written notice of withdrawal must be submitted to usdohad@gmail.com. This notice must state the reason(s) for withdrawal of the abstract and attest that all authors agree that the abstract must be withdrawn. Notification of withdrawal of an abstract must be received not later than 1 week prior to the start of the annual meeting.

10. Disclosure of Affiliations and Conflicts of Interest: Each author must disclose any financial, personal, or professional relationships with other people or organizations that could reasonably be perceived as conflicts of interest or as potentially influencing or biasing their work. Author(s) disclosure(s) must appear on the oral abstract presentation slides or poster presentation board.